Efficacy and safety of modified anti-tubercular treatment(ATT) regimens in treatment of tuberculosis(TB) in patients with underlying chronic liver disease(CLD) Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Evaluation of drug induced liver injury due to anti tuberculous drugs in directly observed daily therapy Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Treatment of patients with extensive TB and concomitant bronchial lesions with some anti-TB drugs delivered via nebulizer Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
The effectiveness of pulmonary TB treatment in patients with organic liver diseases, depending on the way of administration of anti-TB drugs Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Chloroquine as a potential adjunctive therapy in tuberculosis Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014
Side effects of tuberculosis treatment with fixed-dose combinations Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is about drug hypersensitivity reactions? Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016
The effectiveness of TB treatment in patients with gastrointestinal tract disorders, depending on the way of administration of anti-TB drugs Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Efficacy of moxifloxacin instead of ethambutol in the intensive phase of therapy in newly diagnosed pulmonary TB Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Anti-tuberculosis drug concentrations and treatment outcomes in patients with both tuberculosis and HIV infection Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Safety and acceptability of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Restarting biologic agents in rheumatology patients who developed tuberculosis under TNFα-inhibitor treatment Source: International Congress 2015 – Latent TB infection and screening Year: 2015
Opportunities of application of short regimens for MDR-TBat the expense of using intravenous administration of anti-TB drugs during intensive phase Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Advantages of intravenous chemotherapy for tuberculosis patients with viral hepatitis Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Effect of anti-tuberculosis treatment on body composition during the intensive phase Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Impact of food intake on pharmacokinetics(PK) of first-line tuberculosis drugs in treatment-naive patients Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014
Clinical experience of clofazimine in the treatment of MDR-TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016